Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Recent Pat Drug Deliv Formul ; 13(1): 16-36, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30806332

RESUMEN

BACKGROUND: Cancer is a life-threatening global problem with high incidence rates. Prioritizing the prevention of cancer, chemopreventive agents have drawn much attention from the researchers. OBJECTIVE: This review focuses on the discussion of the progress in the development of chemopreventive agents and formulations related to the prevention of oral cancer. METHODS: In this perspective, an extensive literature survey was carried out to understand the mechanism, control and chemoprevention of oral cancer. Different patented agents and formulations have also exhibited cancer preventive efficacy in experimental studies. This review summarizes the etiology of oral cancer and developments in prevention strategies. RESULTS: The growth of oral cancer is a multistep activity necessitating the accumulation of genetic as well as epigenetic alterations in key regulatory genes. Many risk factors are associated with oral cancer. Genomic technique for sequencing all tumor specimens has been made available to help detect mutations. The recent development of molecular pathway and genetic tools has made the process of diagnosis easier, better forecast and efficient therapeutic management. Different chemical agents have been studied for their efficacy to prevent oral cancer and some of them have shown promising results. CONCLUSION: Use of chemopreventive agents, either synthetic or natural origin, to prevent carcinogenesis is a worthy concept in the management of cancers. Preventive measures are helpful in controlling the occurrence or severity of the disease. The demonstrated results of preventive agents have opened an arena for the development of promising chemopreventive agents in the management of oral squamous cell carcinoma.


Asunto(s)
Anticarcinógenos/administración & dosificación , Carcinoma de Células Escamosas/prevención & control , Desarrollo de Medicamentos/métodos , Neoplasias de la Boca/prevención & control , Anticarcinógenos/síntesis química , Antioxidantes/administración & dosificación , Antioxidantes/síntesis química , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/metabolismo , Quimioprevención/métodos , Quimioprevención/tendencias , Composición de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Sistemas de Liberación de Medicamentos/tendencias , Desarrollo de Medicamentos/tendencias , Humanos , Neoplasias de la Boca/diagnóstico , Neoplasias de la Boca/metabolismo , Papillomaviridae/efectos de los fármacos , Papillomaviridae/fisiología
2.
Recent Pat Drug Deliv Formul ; 10(2): 156-64, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26996366

RESUMEN

BACKGROUND: Drug targeting to brain has always been problematic due to Blood-Brain Barrier (BBB), which, does not allow most of the drugs to pass through it as they are hydrophilic and macromolecular drugs. So, in order to bypass the BBB, alternative modes of administration were searched and nasal to brain delivery route was tried by many workers. Such studies yielded patented nano-formulations with the ability to cross blood brain barrier. METHODS: Nanoparticles being smaller in size and large surface area help in increasing the rate of drug permeation to the brain. In this review work, emphasis has been laid on discussion on various works done in the field of nasal delivery of drugs to brain over the last decade. RESULTS: The works that are discussed in this paper show better drug targeting of brain when given through nasal route as nanoparticles. Experiments performed in animal models have clearly exhibited that nano-sized formulations are able to facilitate the delivery of drugs to brain through nose in comparison to tantamount drug solutions. CONCLUSION: However, it is not yet confirmed whether the drug is freed from the formulation in the nasal cavity and then absorbed or the nanoparticles themselves are absorbed and then the drug is released in the CNS. Furthermore, the toxicity studies were not carried out extensively in suitably designed model, which should be considered before going for further studies and application.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Portadores de Fármacos , Sistemas de Liberación de Medicamentos/métodos , Nanomedicina/métodos , Nanopartículas , Preparaciones Farmacéuticas/administración & dosificación , Polímeros/química , Tecnología Farmacéutica/métodos , Administración Intranasal , Animales , Composición de Medicamentos , Humanos , Absorción Nasal , Mucosa Nasal/metabolismo , Permeabilidad , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo
4.
J Microencapsul ; 32(1): 29-39, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25090597

RESUMEN

CONTEXT: The coating material of magnetic nanoparticles plays a great role in drug delivery application. The coatings not only increase the stability of the nanoparticles but also improve the drug release pattern, biocompatibility and mucoadhesivity. OBJECTIVE: Montmorillonite (MMT) containing magnetic iron oxide nanoparticles coated with polyelectrolyte complex (PEC) of carboxymethyl starch-chitosan were prepared for controlled release applications. METHOD: The PEC-coated nanoparticles were characterised by Fourier Transmission Infra-red spectroscopy and X-ray diffraction, scanning electron microscope, transmission electron microscope, and dynamic light scattering. Cytotoxicity study was performed by MTT assay analysis. Mucoadhesivity test was performed by using in vitro wash off and ex vivo method. RESULT: The coating of PEC showed good stability, biocompatibility and mucoadhesivity of the iron oxide magnetic nanoparticles. MMT addition enhanced the swelling, drug loading and release and also the cytotoxicity and mucoadhesivity of the nanoparticles. CONCLUSION: This study revealed that the MMT incorporated PEC of CMS-CS can be effectively used for coating of iron oxide nanoparticles.


Asunto(s)
Isoniazida , Linfocitos/metabolismo , Nanopartículas de Magnetita/química , Ensayo de Materiales , Almidón/análogos & derivados , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Preparaciones de Acción Retardada/farmacología , Femenino , Humanos , Isoniazida/química , Isoniazida/farmacocinética , Isoniazida/farmacología , Linfocitos/citología , Masculino , Almidón/química , Almidón/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...